Table 1.
Demographics and baseline characteristics of COVID‐19 patients
| Number (%) | ||||
|---|---|---|---|---|
| Variables | Total (n = 174) | High TG (n = 78) | Control (n = 96) | p‐value |
| Age in years, median (IQR) | 66.0 (54.7–72.0) | 63.0 (50.0–69.0) | 67.0 (57.0–73.0) | .151 |
| Sex | ||||
| Male | 88 (50.6) | 35 (44.9) | 53 (55.2) | .223 |
| Female | 86 (49.4) | 43 (55.1) | 43 (44.8) | |
| Comorbidities | ||||
| Diabetes mellitus | 51 (29.3) | 27 (34.6) | 24 (25.0) | .182 |
| Hypertension | 80 (46.0) | 34 (43.6) | 46 (47.9) | .467 |
| Cardiovascular disease | 30 (17.2) | 12 (15.4) | 18 (18.8) | .687 |
| Pulmonary disease | 14 (8.0) | 7 (9.0) | 7 (7.3) | .782 |
| Cerebrovascular disease | 10 (5.7) | 3 (3.8) | 7 (7.3) | .515 |
| Chronic kidney disease | 14 (8.0) | 5 (6.4) | 9 (9.4) | .581 |
| Maintenance hemodialysis | 11 (6.3) | 4 (5.1) | 7 (7.3) | .756 |
| Signs and symptoms | ||||
| Fever | 114 (65.5) | 53 (67.9) | 61 (63.5) | .631 |
| Cough | 113 (64.9) | 49 (62.8) | 64 (66.7) | .634 |
| Fatigue | 74 (42.5) | 34 (43.6) | 40 (41.7) | .878 |
| Shortness of breath | 110 (63.2) | 54 (69.2) | 56 (58.3) | .871 |
| Myalgia | 30 (17.2) | 12 (15.4) | 18 (18.8) | .687 |
| Diarrhea | 21 (12.1) | 9 (11.5) | 12 (12.5) | .999 |
| Medication | ||||
| Abidol tablets (200 mg t.i.d.) | 174 (100) | 78 (100) | 96 (100) | 1.000 |
| Methylprednisolone sodium succinate (1–2 mg/kg/d injection for 3–5 days) | 58 (33.3) | 28 (35.9) | 30 (31.3) | .523 |
| Lianhua Qingwen (4 capsules t.i.d.) | 171 (98.3) | 76 (97.4) | 95 (99.0) | .588 |
| Mortality | 29 (16.7) | 19 (23.1) | 10 (11.5) | .023 |
| %SaO2 on admission, median (IQR) | 95.0 (90.0–97.0) | 95.0 (88.5–97.2) | 95.0 (90.0–97.0) | .498 |
Abbreviations: IQR, interquartile range; SaO2, arterial oxygen saturation; TG, triglycerides; t.i.d., three times a day.